Open Access Highly Accessed Research article

Canakinumab relieves symptoms of acute flares and improves health-related quality of life in patients with difficult-to-treat Gouty Arthritis by suppressing inflammation: results of a randomized, dose-ranging study

Naomi Schlesinger1*, Marc De Meulemeester2, Andrey Pikhlak3, A Eftal Yücel4, Dominik Richard5, Valda Murphy5, Udayasankar Arulmani5, Peter Sallstig5 and Alexander So6

Author Affiliations

1 Division of Rheumatology, Department of Medicine, Robert Wood Johnson Medical School, 125 Patterson Street, New Brunswick, NJ 089010, USA

2 Pratique Médicale, Cabinet de Là-Haut, Rue de Marchienne 113, 6534 Gozée, Belgium

3 Moscow State University of Medicine and Dentistry, Clinical-Diagnostic Center MSMSU, Dolgorukovskaya Street 4, Moscow 127006, Russia

4 Baskent University, Faculty of Medicine, Baglica Kampusu, Eskisehir Yolu 20.km, Baglica 06530, Ankara, Turkey

5 Immunology & Infectious Disease Therapeutic Area, Novartis Pharma AG, Lichtstrasse 35, CH-4056, Basel, Switzerland

6 Service de Rhumatologie, Centre Hospitalier Universitaire Vaudois, University of Lausanne, Av. Pierre-Decker 5, CH-1005, Lausanne, Switzerland

For all author emails, please log on.

Arthritis Research & Therapy 2011, 13:R53  doi:10.1186/ar3297

Published: 25 March 2011

Additional files

Additional file 1:

Supplementary Table S1: Demographic and baseline characteristics. Table giving demographic and baseline characteristics of the study population by treatment group.

Format: DOC Size: 216KB Download file

This file can be viewed with: Microsoft Word Viewer

Open Data